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INTRODUCTION
Melanomas are one of the most deadly cancers in the world. 
The rapid increase in their incidence is a serious public health 
problem.[1] Melanomas contribute to >50% of deaths involving 
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ABSTRACT
In this study, we attempted to develop functional liposomes loaded with camptothecin and attached to α‑melanocyte‑stimulating hormone (α‑MSH) 
to target melanoma cells. The liposomes were mainly composed of phosphatidylcholine, cholesterol, and stearylamine, and were characterized by 
the vesicle size, zeta potential, camptothecin encapsulation efficiency, and release behavior. Results revealed that α‑MSH liposomes possessed 
an average size of approximately 250 nm with a surface charge of 60 mV. Camptothecin was successfully entrapped by the targeted liposomes 
with an encapsulation percentage of nearly 95%. The liposomes provided sustained and controlled camptothecin release. Non‑targeted liposomes 
with the drug exerted superior cytotoxicity against melanomas compared to the free control. Cell viability was reduced from 48% to 32% 
compared to conventional liposomes. Peptide ligand conjugation further promoted cytotoxicity to 18% viability, which was a 2.7‑fold decrease 
versus the free control. According to the images of fluorescence microscopy, α‑MSH liposomes exhibited greater cell endocytosis than did 
non‑targeted liposomes and the free control. α‑MSH liposomes were predominantly internalized in the cytoplasm. These findings demonstrate 
that α‑MSH liposomes could enhance the anti‑melanoma activity of camptothecin owing to their targeting ability and controlled drug delivery.
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skin cancers, although they only account for 5% of all skin can‑
cers.[2] Because of their aggressive property, melanomas present 
high therapeutic resistance to classical radiotherapy and chemo‑
therapy.[3] Liposomes, as carriers for drug delivery, can prolong 
circulation times and accelerate tumor uptake, thus improving 
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therapeutic resistance. Liposomes are nano‑sized vesicles consist‑
ing of membrane‑like phospholipid bilayers in an aqueous solu‑
tion. Their biocompatibility, low toxicity, and protection of drugs 
provide an effective strategy of drug delivery to action sites.[4,5]
Currently approved liposomes for anticancer drugs still 
possess some problems such as cardiotoxicity, myelosuppres‑
sion, and alopecia because of insufficient targeting to tumors.[6] 
A promising method to resolve those shortcomings is to decorate 
the liposomal surface with specific proteins or antibodies that 
can bind to receptors on cell membranes.[7] The melanocortin‑1 
receptor (MC1R) belongs to the superfamily of G protein‑coupled 
receptors, which is overexpressed in melanomas. Over 80% 
of metastatic melanomas were identified as displaying the 
MC1R.[8] α‑Melanocyte‑stimulating hormone (α‑MSH) is a tri‑
capeptide that selectively activates the MC1R. It is well known 
for its role in regulating skin pigmentation.[9] It is anticipated that 
carriers can efficiently bind to melanoma cells by conjugating 
peptide ligands. A previous study[10] developed gold nanoparticles 
conjugated with α‑MSH for successful melanoma targeting. 
Nevertheless, toxicity is a concern for nanoparticles made of 
heavy metals. Yagi, et al.,[11] prepared liposomes with α‑MSH via 
C‑terminal conjugation with lipids, which successfully bound to 
melanomas. However, no drug was loaded in the liposomes for 
examining cytotoxicity to melanomas in that study. We tried to 
develop a drug‑loaded liposomal system embedding α‑MSH in 
the present work. Raposinho, et al.,[12] demonstrated that α‑MSH 
derivatization via disulfide bonds displayed increased binding 
affinity and proteolysis resistance. We linked sulfosuccinimidyl 
6‑[3′‑(2‑pyridyldithio)‑propionamide] hexanoate (sulfo‑LC‑SP‑
DP) to the N‑terminus of α‑MSH via disulfide bonds to prepare 
α‑MSH–containing liposomes.
Camptothecin is a natural product used as the model anticancer 
drug in this report due to its ability to kill melanoma cells.[13] The 
insolubility of camptothecin in most biocompatible solvents makes 
it difficult to deliver it to the body by an intravenous injection. 
Many camptothecin analogs were synthesized for clinical use. 
However, camptothecin always shows more potent activity than its 
semi‑synthetic analogs.[14] Liposomes may act as an ideal vehicle 
for camptothecin to expand its clinical applications. We attempted 
to synthesize α‑MSH–containing liposomes and evaluate their 
physicochemical properties, including size, zeta potential, vesicle 
morphology, drug encapsulation, and release profiles. To elucidate 
their targeting ability, the cytotoxicity and cellular uptake were 
examined in the B16F10 melanoma cell line. Free camptothecin 
in dimethyl sulfoxide (DMSO) and liposomes without peptide 
ligands were also used for comparison.
MATERIALS AND METHODS
Materials
Camptothecin, cholesterol, stearylamine, α‑MSH, dithioth‑
reitol (DTT), rhodamine 123, and Sephadex G25 were purchased 
from Sigma‑Aldrich (St. Louis, MO, USA). Hydrogenated soybean 
phosphatidylcholine (SPC, Phospholipon® 80H) was supplied by 
American Lecithin (Oxford, CT, USA). Sulfo‑LC‑SPDP was pro‑
vided by Thermo Scientific (Rockford, IL, USA). Cellulose mem‑
brane (CelluSep® T1, with a molecular weight cutoff of 3500) was 
purchased from Membrane Filtration Products (Seguin, TX, USA).
Preparation of liposomes
Liposomes were prepared by a thin‑film hydration method. 
SPC (1.6%, w/v), cholesterol (0.4%), stearylamine (0.2%), and 
camptothecin (0.04%) were dissolved in chloroform: Methanol 
(2:1) solution for complete solubilization. The solvent was then 
evaporated in a rotary evaporator at 50°C for 30 min. The residual 
solvent was removed under a vacuum for 6 h. The film was hydrat‑
ed with double‑distilled water using a high‑shear homogenizer (Pro 
250, Pro Scientific, Oxford, CT, USA) for 10 min. The resulting 
systems were then subjected to a probe‑type sonicator (VCX 600, 
Sonics and Materials, Danbury, CT, USA) at 35 W for 30 min. 
The total volume of the final products was 10 ml.
Preparation of α‑MSH liposomes
α‑MSH (0.5 ml) in a phosphate‑buffered saline (PBS) 
solution (2 mg/ml) was first modified at its N‑terminus by 
sulfo‑LC‑SPDP. α‑MSH was mixed with 0.5 ml sulfo‑LC‑SPDP 
in DMSO (2 mg/ml) for 5 h at 37°C. Subsequently, 0.1 M DTT 
was added to the mixture at 37°C for 2 h to link the sulfhydryl 
moiety to the N‑terminus of α‑MSH (sulfhydryl‑α‑MSH). Li‑
posomes (2 ml) were reacted with sulfhydryl‑α‑MSH (20‑fold 
molar excess of sulfhydryl‑α‑MSH: Liposomes) at 4°C for 12 h. 
The ‑NH2 group in stearylamine provided the reaction site for 
the carboxylate moiety of sulfhydryl‑α‑MSH. Then the α‑MSH 
liposomes were purified through a Sephadex G25 column and 
validated by matrix‑assisted laser desorption/ionization‑time of 
flight/time of flight (MALDI‑TOF/TOF) mass spectrometry (Ul‑
traflex, Bruker‑Daltonik, Bellerica, MA, USA). Figure 1 shows 
the complete reaction scheme for preparing α‑MSH liposomes.
Vesicle size and zeta potential of liposomes
The average size and zeta potential were determined by photon 
correlation spectrometry (Nano ZS90, Malvern, Worcestershire, 
UK) using a helium–neon laser at a wavelength of 633 nm. A 1:100 
dilution with double‑distilled water was performed before the 
measurement. The determination was repeated three times per 
sample for three different batches.
Transmission electron microscopy
The morphology of liposomes was observed by TEM. A drop 
of liposomal dispersion was pipetted onto a carbon film‑covered 
copper grid to form a thin‑film specimen. Phosphotungstic acid 
at 1% was used to stain the samples. The prepared samples were 
examined and photographed with transmission electron micros‑
copy (TEM; H‑7500, Hitachi, Tokyo, Japan).
Encapsulation efficiency of camptothecin in liposomes
The encapsulation percentage of camptothecin in liposomes 
was measured by an ultracentrifugation method. The liposomal 
dispersion was centrifuged at 48,000 × g at 4°C for 8 min in a 
Beckman Optima MAX® (Beckman Coulter, Fullerton, CA, USA) 
to separate the encapsulated camptothecin from the free form. After 
centrifugation, both the supernatant and precipitate were analyzed 
by high‑performance liquid chromatography (HPLC) to determine 
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the encapsulation percentage (%) of the total camptothecin load in 
the vesicles. The analytical method for camptothecin was described 
in our previous study.[13]
Camptothecin release from liposomes
Camptothecin release was determined using a Franz diffusion 
assembly. A cellulose membrane was mounted between the donor 
and receptor compartments. The donor medium consisted of either 
0.5 ml camptothecin (0.04%) in 30% ethanol/double‑distilled wa‑
ter (free control), conventional liposomes, or α‑MSH liposomes. 
The receptor medium was 5.5 ml of 30% ethanol in pH 7.4 phos‑
phate‑citrate buffer. The available area for release between the com‑
partments was 0.785 cm2. The stirring rate and temperature of the 
receptor were kept at 600 rpm and 37°C, respectively. At appropriate 
intervals, 300‑μl aliquots of the receptor medium were withdrawn 
and immediately replaced with an equal volume of fresh buffer. The 
amount of camptothecin release was quantified by HPLC.
Cell viability assay
The mouse melanoma B16F10 cell line was purchased from 
American Type Culture Collection (Rockville, MD, USA). Cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) heat‑inactivated fetal bovine serum 
and 1% antibiotics (100 U/ml penicillin and 100 U/ml streptomycin) 
at 37°C in a humidified atmosphere with 5% CO2. Cells (10
4) were 
sealed into 96‑well plates and cultured for 24 h. The free control 
or liposomes with or without α‑MSH were used to treat cells. For 
the cell viability determination, intracellular ATP was detected by a 
bioluminescence assay based on an ATP‑dependent luciferase reac‑
tion using a commercial kit as described previously.[15] After a 24‑h 
culture with camptothecin vehicles, 100 μl of the CellTiter‑Glo® 
reagent was added to each well. The mixture was shaken for 2 min 
on an orbital shaker to induce cell lysis. The plate was allowed to 
incubate at room temperature for 10 min to stabilize the luminescent 
signal. Luminescence was measured with a luminometer (Chame‑
leon V, Hidex, Turku, Finland).
Cellular uptake assay
To study the cellular uptake by melanoma cells, 0.03% rhoda‑
mine 123 instead of camptothecin was loaded in liposomes by the 
same preparation process as described in the section “Preparation 
of Liposomes.” Rhodamine 123 is a fluorescent dye that shows 
excitation at 511 nm and emission at 534 nm. Melanoma cells (105) 
were seeded in 24‑well plates (1 ml) and cultured for 24 h. Then, 
either the free control, liposomes, or α‑MSH liposomes with 
rhodamine 123 were added to the plate and incubated for 2 h at 
37°C. The medium was removed, and cells were washed twice 
with PBS. B16F10 cell uptake of rhodamine 123 was imaged 
under fluorescent microscopy (DP‑70, Olympus, Tokyo, Japan). 
The excitation wavelength of the microscopy was set to 488 nm, 
and the green emission of rhodamine 123 was monitored.
Statistical analysis
Unpaired Student’s t‑test was utilized to examine the statistical 
difference between samples. A P value of < 0.05 was considered a 
significant difference. Data are presented as the mean and standard 
deviation (SD). All experiments were independently repeated at 
least three times.
RESULTS
Physicochemical properties
The vesicle size, polydispersity, and zeta potential of liposomes 
with or without α‑MSH were detected by the Zetasizer. Results are 
shown in Table 1. The average size of non‑targeted liposomes was 
estimated to be about 200 nm. The polydispersity index could be 
controlled to a narrow distribution of 0.15, suggesting a homogeneous 
population of vesicles. Compared to conventional liposomes, the 
size of α‑MSH liposomes was significantly larger (253 nm) and the 
size distribution was wider (0.24). Stearylamine produced a positive 
charge on the liposomal bilayers [Table 1]. The zeta potential of 
conventional liposomes was about 57 mV. α‑MSH slightly but sig‑
nificantly (P < 0.05) increased the zeta potential to a value of 60 mV.
Figure 1. Scheme of the chemical reaction for synthesizing sulfhydryl‑α‑melanocyte‑stimulating hormone (sulfhydryl‑α‑MSH) and preparing α‑MSH 
liposomes
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In order to obtain more information about the size and morphol‑
ogy, TEM imaging was used to analyze both types of liposomes. 
As depicted in Figure 2a, the prepared conventional liposomes 
were spherical and compact. The outer morphology was smooth. 
On the other hand, the entire structure of α‑MSH liposomes was 
heterogeneous in shape as shown in Figure 2b. The liposomal size 
estimated by TEM was well correlated with that measured with 
the Zetasizer. An important concern with respect to liposomes as 
drug nanocarriers is the drug loading capacity. The camptothecin 
encapsulation percentages of both formulations exceeded 95% 
of the total drug added to the system [Table 1]. Nearly complete 
entrapment of camptothecin was found for conventional liposomes. 
The encapsulation percentage dropped from 100% to 95% after 
conjugation with α‑MSH [Figure 2].
Camptothecin release from liposomes
A key issue of liposomes as carriers is the feasibility of delivering 
a drug. The camptothecin release percentage was determined as a 
function of time as shown in Figure 3. DMSO was used as the free 
control for camptothecin. The control group exhibited the greatest 
release. A burst release was shown for the free control. Camptothecin 
release from 30% ethanol was almost complete in 24 h. About 59% 
of the camptothecin was released during 48 h. From Figure 3 it can 
be seen that the release rate significantly decreased following lipo‑
somal application. Camptothecin was released in a sustained manner 
when loaded in liposomes. The release percentage–time curve of 
liposomes was fitted by a zero‑order release function. Incorporat‑
ing α‑MSH in the systems slightly promoted camptothecin release; 
nevertheless, this enhancement was not significant (P  > 0.05). 
Non‑targeted and targeted liposomes respectively showed 32% and 
34% drug release after 48 h of application [Figure 3].
Cell viability assay
The cytotoxicity of camptothecin liposomes against B16F10 
melanomas was examined in vitro. An ATP assay was applied for 
the cell viability test, which follows the cellular ATP level as an 
indicator of cell viability. At first, the cell viability was determined 
by free camptothecin in DMSO at different concentrations. Free 
camptothecin induced a dose‑dependent growth inhibition of 
the melanoma cell line with an IC50 of about 50 μM as shown in 
Figure 4. Actually, a further increment of the dose to 100 μM did 
not significantly (P > 0.05) increase the cytotoxicity compared to 
the level at 50 μM. Melanoma cells were exposed to 50 μM camp‑
tothecin to examine the cytotoxicity of liposomes. As demonstrated 
in Figure 5, both liposomal dispersions displayed significantly 
lower (P < 0.05) cell viability compared to the free control. The 
results indicate that α‑MSH liposomes bearing camptothecin were 
more active against melanomas than the conventional systems. 
After 24 h of incubation, cell viabilities after treatment with the free 
control, non‑targeted liposomes, and targeted liposomes were 48%, 
Table 1. The characterization of the liposomes and α‑MSH liposomes by size, zeta potential, and encapsulation efficiency
Formulation Average size (nm) Polydispersity index Zeta potential (mV) Encapsulation efficiency (%)
Conventional liposomes 197.2±1.3 0.154±0.011 56.6±0.5 100.3±1.7
α‑MSH liposomes 252.6±6.4 0.236±0.023 60.1±0.8 95.3±0.3
Each value represents the mean and SD (n=3), MSH: melanocyte stimulating hormone
Figure 3. In vitro release percentage (%)–time profiles of camptothecin 
(at a 0.04% dose) across cellulose membranes from the free control (30% 
ethanol in double‑distilled water), conventional liposomes, and 
α‑melanocyte‑stimulating hormone (α‑MSH) liposomes. Each value 
represents the mean and standard deviation (n = 4)
Figure 4. Viability percentage (%) of B16F10 melanoma cells treated 
with free camptothecin in DMSO at various concentrations. Each value 
represents the mean and standard deviation (n = 3)
Figure 2. Transmission electron microscopic (TEM) photographs 
of (a) conventional liposomes and (b) α‑melanocyte‑stimulating 
hormone (α‑MSH) liposomes at 120,000×. The scale bar is 100 nm
ba
Lin, et al. / Journal of Traditional and Complementary Medicine 3 (2013) 102‑109
106
32%, and 18%, respectively. Blank liposomes without the drug were 
also tested for cytotoxicity. There was no obvious effect of the blank 
liposomes on growth inhibition of the melanoma cells (data not 
shown). This suggests that the cytotoxicity toward the melanoma 
was predominantly a result of camptothecin itself [Figures 4 and 5].
Cellular uptake assay
To track the cellular internalization of liposomes, rhodamine 123 
was included in the liposomes for imaging. Figure 6 summarizes the 
imaging profiles of cellular uptake by free and liposome‑encapsulated 
rhodamine 123 under fluorescent microscopy. As can be observed 
in Figure 6A, there was nearly no fluorescence signal in melanoma 
cells after free rhodamine 123 treatment. The fluorescence intensity 
was significantly enhanced by the addition of liposomes to melanoma 
cells [Figure 6b and c]. The fluorescence was mainly derived from the 
cytoplasm rather than the cell nuclei or membranes. This indicates 
that rhodamine 123 included in liposomes had been introduced into 
B16F10 cells. More intense fluorescence from α‑MSH liposomes 
in the cytoplasm was seen compared to non‑targeted liposomes, 
suggesting that targeted liposomes efficiently bound to melanoma 
cells via the α‑MSH ligands. Cells appeared evenly fluorescent, 
demonstrating widespread distribution of the vesicles [Figure 6].
DISCUSSION
The success of cancer therapy is greatly dependent upon 
carriers developed to deliver the drugs. Liposomes and related 
nanomaterials are increasingly being employed as nanocarriers for 
drugs due to their ability to lessen the adverse effects and maximize 
their therapeutic activity. Efficient tumor targeting is promising by 
conjugating the liposomal surface with ligands capable of binding 
to cell receptors. Based on the capability of α‑MSH to selectively 
bind to melanomas but not normal cells, we attempted to develop 
α‑MSH–conjugated liposomes incorporating camptothecin, which 
is not a regular anticancer drug candidate because of the lack of 
feasible carrier systems. The experimental results showed a target‑
ing efficiency of α‑MSH liposomes to melanomas according to the 
cell‑viability and cellular‑uptake studies, whereas conventional 
liposomes exhibited less‑efficient activity. Controlled and sustained 
camptothecin release was detected with the liposomal systems.
Sulfo‑LC‑SPDP was used to form amine‑to‑sulfhydryl linkages 
for α‑MSH conjugation to stearylamine‑containing liposomes. The 
liposomes were prepared by thin‑film hydration and subsequent 
high‑pressure homogenization and sonication. α‑MSH may reside 
on the liposomal bilayers, resulting in an increment in the vesicle 
size from 200 to 250 nm. α‑MSH on the liposomal surface also 
contributed to the heterogeneous shape of the vesicles shown in 
the TEM image [Figure 2]. The polydispersity values indicated 
a narrow and unimodal vesicle size distribution (<0.25). Stearyl‑
amine produced a positive charge on the surface of the liposomes. 
No remarkable difference in the zeta potential was observed after 
α‑MSH conjugation, although the value slightly increased from 
57 to 60 mV. This could have been due to the presence of some 
amine groups located in α‑MSH’s structure. The zeta potential 
can act as a predictor of physical stability. Liposomal aggregation 
and fusion are less likely to occur with a zeta potential of >│30│ 
mV because of electrical repulsion.[3,16] Our liposomes fulfilled 
this criterion. Another benefit of cationic liposomes is that they 
encourage interactions with negatively charged cellular surfaces.
The liposomes showed an entrapment efficiency of >95% for 
drug loading. Since camptothecin is a lipophilic molecule with a 
log P (partition coefficient) of 2.42,[17] it can readily be interca‑
lated in the phospholipid bilayers of liposomes with high affinity. 
Encapsulation was found to be slightly reduced when coupling 
to vesicles with α‑MSH. The rigidity of liposomal SPC bilayers 
Figure 5. Viability percentage (%) of B16F10 melanoma cells treated 
with camptothecin in the free control, conventional liposomes, and 
α‑melanocyte‑stimulating hormone (α‑MSH) liposomes at a concentration 
of 50 μM. Each value represents the mean and standard deviation (n = 3). 
*P < 0.01; **P < 0.001
Figure 6. Images of fluorescent microscopy of rhodamine 123 uptake by the (a) free control, (b) conventional liposomes, and (c) α‑melanocyte‑stimulating 
hormone (α‑MSH) liposomes by B16F10 melanoma cells
cba
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might be disrupted by mixing with α‑MSH, leading to the greater 
permeability of the α‑MSH–containing membrane.
Drug release was evaluated by determining the release per‑
centage across cellulose membranes. The mean pore size of the 
membrane was <10 nm,[18] and so only very small vesicles could 
diffuse through it. Almost only free camptothecin molecules were 
able to permeate through the membrane. Camptothecin release from 
the free control did not reach 100% by the end of the experiment. 
A ~60% release percentage was detected over 48 h. This may have 
been due to utilization of the Franz diffusion assembly. Since the 
definite receptor volume (5.5 ml) and diffusion area (0.785 cm2) are 
limited, drug loading in the receptor is restricted. There is no longer 
a concentration gradient between the donor and receptor compart‑
ments. Yet, this release platform is still valuable for distinguishing 
release profiles from different formulations. Phospholipid bilayers 
are a diffusion barrier for drug delivery. Cholesterol interacting with 
SPC also plays an essential role in increasing membrane rigidity 
and reducing the permeability of the bilayers.[19,20] The sustained 
and controlled release of camptothecin from liposomes may be at‑
tributed to high encapsulation, strong intercalation of camptothecin 
within the bilayers, and the barrier function of the bilayers. The 
slightly higher drug that leached from α‑MSH liposomes com‑
pared to conventional liposomes was due to lower encapsulation 
in this targeted carrier. However, the difference was not large and 
could be neglected. In a previous investigation,[21] α‑MSH with 
an amphiphilic property had a tendency to increase leakage of 
liposomal membranes. This phenomenon was not observed in our 
case. The release profiles demonstrated that α‑MSH liposomes are 
a promising carrier for controlled release to administer camptoth‑
ecin. Sustained release is a feature often correlated with improved 
drug efficacy and pharmacokinetics.[22] It is especially important 
for camptothecin since serum albumin in the blood can open the 
camptothecin lactone ring and shorten the circulation half‑life.[23] 
Liposomal incorporation of camptothecin can help retain the ac‑
tive lactone form. Liposomes also reduce camptothecin toxicity,[24] 
since liposomes prevent a burst effect of drug exposure in the body.
Camptothecin can induce apoptosis of melanoma cells, which 
is essentially dependent upon p53 and mitochondrial pathways. 
Caspase‑2 and p73 are also involved in apoptotic pathways with 
camptothecin.[25] An in vitro cell viability assay of camptothecin 
showed that the cytotoxicity of α‑MSH liposomes was the great‑
est among all formulations tested, followed by non‑targeted 
liposomes and the free control. The cytotoxicity of drug‑loaded li‑
posomes may be dominated by extracellular drug release from 
liposomes and the intracellular uptake of intact liposomes.[26] The 
direct penetration of liposomes may be a predominant route for 
cytotoxicity because of the slow camptothecin release and limited 
growth‑inhibition activity of free camptothecin.
According to the results of the cellular uptake assay, α‑MSH 
ligands promoted cell internalization via the MC1R. The uptake 
performance was greater than that of non‑targeted liposomes which 
appeared to enter cells by less‑efficient pathways. The therapeutic 
efficiency of anticancer drugs is largely dependent on the activity 
of cellular uptake.[27] Cellular uptake by various formulations was 
well correlated to the cytotoxic activity of camptothecin. This 
indicates that inhibition of cell proliferation was predominated 
by the actual intracellular drug amount. The C‑ or N‑terminal 
derivatization of α‑MSH is an important character in the specific 
binding efficiency to the MC1R. Schiöth et al.,[28] demonstrated 
that C‑terminal modification weakened α‑MSH’s affinity to the 
receptor, whereas an N‑terminal addition did not influence the 
binding affinity. In this study, we developed liposomes conjugated 
with α‑MSH at the N‑terminus. The success in eliciting effective 
cellular internalization was most likely due to liposomal endocy‑
tosis. It is necessary for the liposomes to enter cells and diffuse 
through the viscous cytosol to access particular targets where the 
action sites are located. Endocytosis is involved in the fusion of 
liposomal surfaces with cell membranes. Receptor‑mediated en‑
docytosis basically results in the entry of internalized ligands by 
the lysosomal route, leading to their destruction.[29]
The failure of cellular uptake by liposomes is usually attributed 
to anionic vesicles that are repelled by negatively charged cell 
membranes.[30] Cationic liposomes are thought to easily interact with 
cell plasma membranes, subsequently enhancing their uptake into 
cells.[31,32] Another potential of cationic liposomes is their preferential 
uptake by interstitial tumor tissues and leaky tumor vasculature.[2,33] 
When administered by an intravenous route, the cationic form can 
obviate plasma protein adsorption and the complement system,[5,34] 
thus prolonging the half‑life of the carriers. Helper lipids such as 
cholesterol also assist the cellular internalization of liposomes.[2,35] It 
was suggested that even in the absence of specific ligands attached 
to the liposomal surface (conventional liposomes), vesicles could 
localize into cells due to the positive charge and cholesterol on the 
liposomes. In addition to the above‑mentioned mechanisms, lipo‑
somes can bypass efflux transporters, thus increasing the anticancer 
activity of the drugs.[36] Further study is necessary to elucidate this 
mechanism.
When entering the cancer cells, drug distribution between the 
cytoplasm and nuclei can largely influence the anticancer activ‑
ity.[37] Camptothecin is a topoisomerase inhibitor that interferes 
with topoisomerase function of DNA replication in the nuclei. 
According to fluorescence imaging of cellular uptake, the green 
signal was mainly located in the cytoplasm, not in the nuclei. The 
proposed process for the anticancer effect of α‑MSH liposomes is 
that after liposomal internalization to the cytoplasm, degradative 
enzymes in the cytosol break down the liposomal membranes 
and release the drug. Or drug release from liposomes in the cy‑
toplasm may become faster in the presence of endolysosomes.[37] 
Subsequently, the drug diffuses to the nuclei to trigger apoptotic 
procedures. p53 and its transactivated targets may induce camp‑
tothecin‑related apoptosis of melanoma cells by translocating into 
mitochondria,[25,38] where they form complexes with proteins and 
enhance the loss of the mitochondrial membrane potential and 
its transition. This indicates that camptothecin might not neces‑
sarily have to target nuclei, but could reside in the cytoplasm to 
elicit its cytotoxicity against melanomas. A great accumulation 
of liposomes in the cytoplasm would be helpful to achieve this.
CONCLUSIONS
The experimental data presented in this study indicate that 
α‑MSH can be utilized to efficiently ferry liposomes for mela‑
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noma targeting. Potent cytotoxicity against melanoma cells was 
observed after loading camptothecin as the model drug. Fluorescent 
microscopic imaging showed that most liposomes were located in 
the cytoplasm after cell internalization. Sustained and controlled 
camptothecin release was achieved after being loaded into lipo‑
somes, which was due to the high encapsulation efficiency and 
strong interaction with the phospholipid bilayers. It is possible 
that the adverse effect of camptothecin can be reduced by α‑MSH 
liposomes because peptide ligands can selectively and specifi‑
cally target melanoma cells, while minimizing the distribution to 
normal cells and tissues. The high efficiency of cellular uptake 
and cytotoxicity of α‑MSH liposomes are particularly important 
for melanomas, since these malignant tumors are highly resistant 
to conventional chemotherapy and lack a satisfactory therapy 
with sustained responses. Although our findings mainly refer to 
in vitro cell line experiments, it is evident that the liposomal ap‑
plication with α‑MSH is a promising approach to overcome the 
drug resistance of melanomas. Further in vivo studies are needed 
and are in progress to explore the efficacy of α‑MSH liposomes 
for future applicability.
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